bluuebunny/crossref_metadata_2025_split huggingface dataset:
583-P: Psychosocial Outcomes among Users and Nonusers of Open-Source Automated Insulin Delivery Systems: Findings from an International Survey of Adults with Type 1 Diabetes
Authors: SCHIPP JASMINE , HENDRIECKX CHRISTEL , BRAUNE KATARINA , O'DONNELL SHANE , BALLHAUSEN HANNE , CLEAL BRYAN , WÄLDCHEN MANDY , KNOLL CHRISTINE , GAJEWSKA KATARZYNA A. , SKINNER TIMOTHY C. , SPEIGHT JANE 
Published: May 2022

Background: Use of open-source automated insulin delivery (AID) is associated with improved psychosocial outcomes among people with type 1 diabetes (T1D) . However, research to date has been qualitative or used study-specific single items. There is a need for quantitative research using validated measures in larger samples.
Method: We conducted an international online survey to examine the psychosocial outcomes of open-source AID users and non-users. Validated questionnaires assessed diabetes-specific quality of life (QoL) , impact of the COVID-pandemic on diabetes-specific QoL, diabetes specific-positive well-being, diabetes treatment satisfaction, diabetes distress, fear of hypoglycaemia, general emotional well-being, and subjective sleep quality.
Results: 587 participants completed at least one questionnaire, including 447 adults using open-source AID (mean age 43, 42% women) and 140 non-users (mean age 40, 64% women) . Table 1 shows significant between-group differences for all questionnaire scores.
Discussion: Adults with T1D using open-source AID report significantly better psychosocial outcomes than non-users. Due to the cross-sectional design of this study, we cannot make any causal inferences about the use of these devices. Further research is needed to examine the reasons for these differences.

Disclosure
J.Schipp: None. T.C.Skinner: None. J.Speight: Advisory Panel; Insulet Corporation, Research Support; Novo Nordisk, Sanofi. C.Hendrieckx: None. K.Braune: None. S.O'donnell: None. H.Ballhausen: None. B.Cleal: None. M.Wäldchen: None. C.Knoll: None. K.A.Gajewska: None.

Funding
European Commission Horizon 2020 (823902)
626-P: TheraKey Diabetes 3.0 App: Better Self-Management, Well-Being, Adherence, and Less Diabetes Distress of People with Diabetes
Authors: KULZER BERNHARD , EHRMANN DOMINIC , ROOS TIMM , HERMANNS NORBERT 
Published: May 2022

Aim: The TheraKey Diabetes 3.0 app supports people with diabetes (PwD) during diabetes diagnosis and in the further course of the disease by providing personalized content (e.g., information, graphics, educational videos, testimonials, worksheets, interactive elements) , knowledge and skills for better self-management and coping with the diabetes disease or therapy in everyday life. This study examined the effect in terms of patient-reported outcomes.
Methods: Online survey of users of MyTherakey Diabetes 3.0 with a pre-post design at 4 (t1) and 12 weeks (t2) . 185 PwD (15,1% type 1 diabetes (T1D) , 79.5% type 2 diabetes (T2D) , 43,2% female, average age 53.5 years, diabetes duration 3,6 (± 7,2) years, BMI 32,3 (± 7,8) kg/m², 34,6% insulin therapy, HbA1c 8,3 ± 2,5%) . Response rate at t2: 55% (n=105) . Diabetes Self-Management: Diabetes Self-Management Questionnaire (DSMQ) , Problem Areas in Diabetes Scale (PAID-5) . Well-being: WHO-5. Active Patient Participation: Patient Activation Measure (PAM-13D) . Self-efficacy expectancy: General Self-efficacy Scale (GSE) . Health literacy: European Health Literacy Survey (HLS-EU-Q16) . Adherence: MARS D.
Results: (t2) : DSMQ: 10,5 ± 10,8/13,3 ± 9,5, p&lt;.0 (t1 p&lt;.001) . WHO-5: 10,5 ± 4,4/11,7 ± 4,1, p=.0 (t1 p= .006) . PAID-5: 33,4 ± 22,5/29,6 ± 21,5, p=.015 (t1 p=.181) . MARS-D: 6,3 ± 1,7/6,8 ± 2,5, p=.022 (t1 p=.432) . PAM-13D: 42,7 ± 4,8/43,4 ± 5,1, p=.136 (t1 p=.426) . GSE: 21,4 ± 5,1/21,8 ± 5,0, p=.297 (t1 p=.167) . HLS-EU-Q16: 13,8 ± 7,4/12,4 ± 8,1, p=.036 (t1 p=.793) . Subgroup analyses show that PwD with short (&lt; 1 year) and long duration of diabetes (&lt; 5 years) and PwD-T2D benefit most.
Conclusion: After 3 months of using the diabetes app, patient-relevant benefits can be observed in terms of improved self-management, better well-being, reduced diabetes-related burden, and better adherence. It remains unclear why health literacy is declining. The TheraKey 3.0 can positively support PwD in managing their diabetes.

Disclosure
B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care. D.Ehrmann: Advisory Panel; Dexcom, Inc., Consultant; mySugr, Roche Diabetes Care, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. T.Roos: None. N.Hermanns: Advisory Panel; Abbott Diabetes, Research Support; Becton, Dickinson and Company, Roche Diagnostics, Speaker's Bureau; Berlin-Chemie AG, Novo Nordisk, Sanofi.
699-P: Time-Restricted Eating Did Not Alter Glycemic Variability in Humans Who Are Overweight and without Diabetes
Authors: MEHFOOZ AYESHA , LEE YEE LIONG , WANG QI , CHOW LISA S. 
Published: May 2022

Background: Time-restricted eating (TRE) is increasingly popular for weight loss, yet its effects on glycemic measures remain unclear. Using continuous glucose monitor (CGM) worn for 2 weeks at baseline and end-intervention, we hypothesized that TRE may reduce glycemic variability compared to unrestricted eating (non-TRE) in patients who are overweight and without diabetes.
Method: Participants (17 women and 3 men; mean [SD] age: 45.5 [12.1] years; BMI 34.1 [7.5] kg/m2) without self-reported diabetes (HbA1c 5.5 [0.4]) who had prolonged eating window (15.4 [0.9] hours) were randomized to a 12 week intervention of either TRE (n=11: 8-hour window, unrestricted eating within window) versus non-TRE (n=9: unrestricted eating) . Each participant wore a blinded CGM (Freestyle Libre Pro) for 2 weeks prior to randomization and at end-intervention (week 11-12) . At each time point, multiple measures of glycemic variability were calculated from the raw CGM data. This is a secondary analysis of a previously published study where 12 weeks of TRE did not alter HbA1c.
Result: Between the TRE and non-TRE groups in the pre and end-intervention periods, there was no statistical difference in any of the calculated glycemic variability measures: including, time in range (TIR) , standard deviation (SD) , coefficient of variation (CV) , continuous overlapping net glycemic action (CONGA) , liability, Index, J-index, low and high blood glucose index (LBGI/HBGI) , glycemic risk assessment diabetes equation (GRADE) , mean of daily differences (MODD) , average daily risk range (ADRR) , mean amplitude of glycemic excursions (MAGE) , mean of daily differences (MODD) , Area Under Curve (AUC) , and Glucose Management Indicator (GMI) .
Conclusion: In patients who are overweight without diabetes, TRE did not alter CGM-measured glycemic variability. Further studies regarding TRE effects on glycemic variability should focus on participants with diabetes.

Disclosure
A.Mehfooz: None. Y.Lee: None. Q.Wang: None. L.S.Chow: Other Relationship; Dexcom, Inc.
707-P: Effectiveness of Breathe Well-Being Diabetes Reversal Program in Achieving Diabetes Remission
Authors: GOYAL PAWAN K. , PATRA SURAJEET K. , KAICKER ADITYA , VERMA ROHAN , GOEL SEEMA , REHMAN SALEHA , JANGID RUPALI , MADHUSUDHANA VENUGOPAL 
Published: May 2022

Introduction: Breathe Well-being Diabetes Reversal Program (BDRP) provides personalized Lifestyle Management (LSM) including coaching on diet and exercise as needed by individuals with type 2 diabetes mellitus (T2DM) along with tracking their blood glucose levels, weight, and physical activity.
Objective: To evaluate the effectiveness of BDRP for achieving remission in individuals with T2DM in India.
Methodology: This observational study had three cohorts (1:1:1) who were treated with: (1) BDRP with doctor-prescribed medication, (2) BDRP with doctor-prescribed medication and personalized stress reduction module, and (3) Only doctor-prescribed medication (control group) . Program adherence level was categorized as high (H: &gt;70%) , medium (M: ≥50%-&lt;70%) , and low (L: &lt;50%) ; H and M data of cohorts 1 and 2 are presented here. Program was provided for 4 months, and individuals followed up at 7, 10, 13, 16, and 19 months. Informed consent was obtained.
Results: The study included 181 individuals with an average age of 53.1 years, of which 1 (55.8%) were male. Overall, 46.7% (28) and 54.1% (33) individuals in cohorts 1 and 2 showed H and M adherence. Cohorts 1 and 2 showed 1.0% and 1.3% average HbA1c reduction vs. 0.3% with cohort 3 (overall population) after 4 months. At 4 months, in cohort 1, HbA1c levels &lt;6.5% were observed in 32.1% individuals, which increased to 60.7%, 67.9%, and 78.6% at 7, 10, and 19 months vs. 36.4% individuals in cohort 2, which increased to 51.5%, 69.7%, and 81.8% at 7, 10, and 19 months, respectively. In cohorts 1 and 2, medication withdrawal was observed in 89.3% and 90.9% individuals at 13 months which was maintained up to 19 months.
Conclusion: BDRP was effective in achieving remission in individuals with T2DM in India. BDRP with personalized stress reduction module had better outcomes comparatively. Digital therapeutics could be a potential approach in achieving diabetes remission in Indian settings.

Disclosure
P.K.Goyal: None. S.K.Patra: Employee; Breathe Well-being. A.Kaicker: None. R.Verma: None. S.Goel: Employee; Breathe Well-being. S.Rehman: None. R.Jangid: None. V.Madhusudhana: None.
716-P: Systolic Blood Pressure Reduction with Tirzepatide across SURPASS Program: A Mediation Analysis Using Weight Loss as a Factor
Authors: LINGVAY ILDIKO , MOSENZON OFRI , BROWN KATELYN , CUI XUEWEI , LANDO LAURA FERNANDEZ , PATEL HIREN 
Published: May 2022

Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes. Across the SURPASS 1-5 clinical studies, TZP 5, and 15 mg demonstrated significant improvements in HbA1c (-1.9 to -2.6%) , body weight (-6.6 to -13.9%) and systolic blood pressure (SBP) (-2.8 to -12.6 mmHg) at primary endpoint. Post-hoc mediation analyses were conducted to evaluate weight loss dependent (WL-D) and independent (WL-IND) effects of TZP on SBP reductions across 5 SURPASS studies. The difference in mean SBP change from baseline at 40-weeks (Total effect) between TZP and comparator group was -1.3 to -5.1 mmHg (TZP 5 mg) , -1.7 to -6.5 mmHg (TZP mg) and -3.1 to -11.5 mmHg (TZP 15 mg) . The contribution of WL-D and WL-IND effects on these treatment differences are presented below (Figure) . In SURPASS-4 study which enrolled patients with established cardiovascular disease, WL-IND effects explained 33% to 57% of difference in SBP change between TZP and insulin glargine groups, with the remainder of 67% to 43% of the effect being WL-D. In a pooled analysis of SURPASS 1-5 studies, there was a significant (p&lt;0.001) but weak correlation (r = 0.18 to 0.22) between change in body weight and SBP. In conclusion, TZP induced SBP reduction was primarily mediated through weight loss, with different degrees of contributions from weight loss independent effects across the different trials.

Disclosure
I. Lingvay: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Mannkind, TARGET PharmaSolutions; Valeritas;; Altimmune; DataRevive; Click; Medscape Duke CRI; Janssen Pharma; Bayer; Intercept, Novo Nordisk, Sanofi, Zealand Pharma A/S. Consultant; Novo Nordisk. Research Support; NovoNordisk; Mylan; Merck, Sanofi. O. Mosenzon: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, BOL Pharma, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk, Sanofi. Research Support; AstraZeneca, Novo Nordisk. Speaker's Bureau; AstraZeneca, Bayer AG, Eli Lilly and Company, Novo Nordisk, Sanofi. K. Brown: Employee; Eli Lilly and Company. X. Cui: Employee; Eli Lilly and Company. L. Fernandez Lando: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. H. Patel: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.

Funding
Eli Lilly and Company
719-P: Tirzepatide Induces Weight Loss in Patients with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies
Authors: KWAN ANITA , MALDONADO JUAN M. , WANG HUI , RASOULI NEDA , WILDING JOHN 
Published: May 2022

Tirzepatide (TZP) is a novel once-weekly dual GIP and GLP-1 receptor agonist evaluated in patients with type 2 diabetes (T2D) . Five Phase 3 SURPASS (S) trials have demonstrated safety and shown robust efficacy of TZP in improvement of glycaemic control and body weight (BW) in adults with T2D. To understand whether the weight-lowering effects of TZP are dependent on baseline BMI, we conducted subgroup analyses of S-1 through -5. BW change in the BMI subgroups (Subgroup 1 [&lt;27 or ≥27 kg/m2] and Subgroup 2 [&lt;30; ≥30 to &lt;35; ≥35 kg/m2]) at primary endpoint was assessed in patients while on treatment without rescue medication (efficacy estimand) in the modified intention-to-treat (mITT) population, defined as all randomized patients who received at least one dose of study drug. All TZP doses (5, 10, 15 mg) lowered BW in patients with T2D irrespective of baseline BMI in both subgroups (p&lt;0.001) . The weight reductions were generally dose-dependent and absolute weight change was generally greater in higher BMI categories. TZP-treated patients with T2D experienced weight loss across a spectrum of mean baseline BMI values in S-1 through -5 studies. The most frequent adverse events were GI-related events that were mild to moderate in severity and occurred during the dose-escalation period.

Disclosure
A.Kwan: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. J.M.Maldonado: Employee; Eli Lilly and Company. H.Wang: None. N.Rasouli: Advisory Panel; Eli Lilly and Company, Novo Nordisk, Sanofi, Research Support; Allergan, Eli Lilly and Company, Novo Nordisk. J.Wilding: Advisory Panel; Alnylam Pharmaceuticals, Inc., AstraZeneca, Eli Lilly and Company, Mundipharma, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Sanofi, Research Support; AstraZeneca, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited.

Funding
Eli Lilly and Company
724-P: A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects
Authors: PIRNER MARK A. , LIN JING , LIU FENG , YAO LILI , ZETTLER MARJORIE E. , VALACER DAVID J. 
Published: May 2022

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized and effective class of glucose-lowering agents for the treatment of patients with type 2 diabetes mellitus (T2DM) . To date, all market-authorized GLP-1 RAs are peptides, and only one is administered orally. RGT-075 is a novel, orally bioavailable, small-molecule GLP-1 RA which has shown therapeutic potential in animal models of T2DM. The results of a first-in-human study of RGT-075 are presented.
Methods: A phase 1, randomized, double-blind, placebo-controlled study was conducted to investigate the safety, tolerability, and pharmacokinetics of single escalating oral doses of RGT-075 (15-280 mg) in healthy adult volunteers. Seven cohorts of 8 subjects were enrolled and randomized to treatment with RGT-075 or matching placebo (6 active/2 placebo per cohort) . Plasma and urine samples were collected over 48 hours post-dose and analyzed for RGT-075 concentrations.
Results: A total of 56 healthy adults (64% male, mean age 42.5 years) participated in the study. Treatment-emergent adverse events (TEAEs) were reported by 28 of 56 (50%) subjects (24 subjects treated with RGT-075 and 4 subjects treated with placebo) . There were no serious adverse events, deaths or TEAEs that led to early withdrawal. The majority of TEAEs were considered mild, and the most common TEAEs related to study drug were nausea, vomiting, and headache. Maximum tolerated dose was not reached. Single oral doses of RGT-075 (15-280 mg) resulted in linear increases in Cmax, AUClast, and AUCinf with ascending doses through 240 mg. Mean elimination half-life ranged from 6.3-11.7 hours. Renal clearance of RGT-075 was low to negligible.
Conclusion: Overall, single RGT-075 doses between 15-280 mg were safe and well-tolerated in healthy volunteers. Further clinical development of RGT-075 as a once-daily, oral therapy for T2DM is underway.

Disclosure
M.A.Pirner: Employee; Regor Pharmaceuticals, Inc. J.Lin: None. F.Liu: Employee; Regor Pharmaceuticals Inc. L.Yao: None. M.E.Zettler: Employee; Cardinal Health, Regor Pharmaceuticals Inc. D.J.Valacer: Employee; Regor Pharmaceuticals, Inc.
736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity
Authors: GOMEZ JUANA CARRETERO , CARRASCO-SÁNCHEZ FRANCISCO JAVIER , FERNANDEZ JOSE MARIA , CASADO PEDRO ,   PANISH SOCIETY OF INTERNAL MEDICINE DIABETES,   NUTRITION AND OBESITY WORKING GROUP OF S, AREVALO LORIDO JOSE CARLOS , GONZÁLEZ JOSE PABLO MIRAMONTES , SEGÍ-RIPOLL JOSÉ MIGUEL , ENA JAVIER 
Published: May 2022

Aim: To assess the efficacy of Semaglutide on liver steatosis/fibrosis indexes.
Methods: Observational, multicenter study. Steatosis/fibrosis were determined by HSI (&lt;30 rule out, &gt;36 steatosis) and FIB-4 (&lt;1.3 rule out, &gt;2.67 fibrosis) .
Results: 213 patients (46.9% women) , age 64 (19) years. Variables and 24 wk changes are shown in table 1. 100% of patients had altered steatosis biomarkers (HSI 47.9 (8.2)) , 10.8% fibrosis (FIB-4&gt; 2.76) . A significant reduction in HSI [-2.36 (95%CI 1.83-2.9) p&lt;0.0000] and FIB-4 [-0.075 (95%CI0.015-0.14) p&lt;0.016] were found (Table 1) . There was a correlation between weight loss and HSI, GGT or TyG improvement (figure 1) .
Conclusion: Our results show a beneficial effect of Semaglutide on steatosis that goes beyond glucose control, and it is related mainly with weight loss and decline in biomarkers.

Disclosure
J.Carretero gomez: None. F.Carrasco-sánchez: None. J.Fernandez: Advisory Panel; Boehringer Ingelheim International GmbH, Daiichi Sankyo, Lilly Diabetes, Novartis Pharmaceuticals Corporation, Sanofi Genzyme, Speaker's Bureau; Amgen Inc., Novo Nordisk Foundation. P.Casado: None. P.Diabetes, nutrition and obesity working group of s: n/a. J.Arevalo lorido: None. J.Miramontes gonzález: None. J.Segí-ripoll: None. J.Ena: None.
739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study
Authors: LAJARA ROSEMARIE , HELLER CAROLINE , PANTALONE KEVIN M. , LEW ELISHEVA , LI XUAN , DEX TERRY A. , KILPATRICK RACHEL 
Published: May 2022

Aim: Premixed insulin (premix) , conventionally administered twice daily, is often used in the US to treat T2D that is suboptimally controlled with BI, particularly for people with consistent eating patterns who require affordable treatment. This analysis evaluated use of once daily iGlarLixi vs. premix on T2D outcomes.
Method: This retrospective analysis of the US Optum Clinformatics database compared outcomes in adults (≥18 y) with T2D who previously received BI and newly initiated iGlarLixi or premix. Persistence (primary endpoint) , adherence, healthcare resource utilization (HRU) , costs, any hypoglycemia, and HbA1c change were assessed at 12 months.
Results: After propensity score matching, cohorts (n=834 each) were well balanced with respect to age, HbA1c, use of oral agents, BI, and HRU. The primary endpoint was met with persistence being statistically significantly higher for iGlarLixi vs. premix at 12 months. Adherence and HbA1c reduction were similar between groups, whereas hypoglycemia rates, HRU, and costs were numerically lower for iGlarLixi (Table) .
Conclusion: In this observational study, once daily iGlarLixi was an effective post-BI treatment with higher treatment persistence than premixed insulin, with similar adherence and HbA1c reduction, and numerically lower hypoglycemia rates, HRU, and costs.

Disclosure
R.Lajara: None. C.Heller: Consultant; Sanofi, Employee; Aetion. K.M.Pantalone: Consultant; AstraZeneca, Bayer AG, Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Bayer AG, Merck & Co., Inc., Novo Nordisk, Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Merck & Co., Inc., Novo Nordisk. E.Lew: Employee; Sanofi. X.Li: Employee; Eisai Co., Ltd., Sanofi. T.A.Dex: Employee; Sanofi, Stock/Shareholder; Pfizer Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc. R.Kilpatrick: Speaker's Bureau; Abbott Diabetes, Amgen Inc., Novo Nordisk, Sanofi.

Funding
Sanofi
751-P: Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes—Six-Months Results from the Real-World STEMT Trial
Authors: MERTENS JONATHAN , DE WINTER HENNAH T. , MAZLOM HADI , PEIFFER FRIDA W. , DIRINCK EVELINE L. , BOCHANEN NIELS , VAN GAAL LUC F. , DE BLOCK CHRISTOPHE 
Published: May 2022

Introduction: the SUSTAIN trials have shown significant improvements in weight and HbA1c levels in people with type 2 diabetes, but the effect and safety of semaglutide in people with type 1 diabetes (T1D) has not been explored yet.
Aims & Methods: In this real-world exploratory study 1.0 mg semaglutide once-weekly was started in adults with T1D and overweight/obesity. To be included, people needed to have stable glycemic control (ΔHbA1c &lt; 0.3 %) , bodyweight (Δ &lt; 3 %) , and insulin type and dose (Δ insulin dose &lt; 5 %) in the last year. Pregnancy or pregnancy wish also was an exclusion criterion. Weight, total daily insulin dose (TDI) and HbA1c were assessed at start and at six months.
Results: Twenty subjects (55 % males, mean age 46.3 ± 9.9 y, diabetes duration 29.6 ± 12.5 y, HbA1c 7.4 ± 0.6 %) were included. Body mass index (BMI) was 33.0 ± 4.4 kg/m2 at baseline, with 80 % of subjects being obese. Two subjects discontinued treatment, both due to gastrointestinal intolerance. Mean bodyweight evolution was -8.5 ± 7.8 kg, ranging between +1.5 and -24.7 kg. Three subjects experienced mild weight gain (ranging 0.2 to 1.5 kg) . Relative weight loss ≥ 5 % was attained in 60 % of cases, and 40 % reached ≥ % weight loss. Mean HbA1c reduction was 0.3 ± 0.7 %, with six subjects (30 %) not showing a reduction in HbA1c. An HbA1c reduction of ≥ 0.5 % was seen in 35 % of cases. A moderate correlation was seen between weight loss and HbA1c reduction (r = 0.52, p = 0.020) . Relative TDI reduction was 13.5 % (IQR 17.8) .
Conclusion: Adding semaglutide 1.0 mg once-weekly in people with T1D was safe, well-tolerated and resulted in promising effects on weight, insulin requirement and glycemic control.
Acknowledgements: JM and HDW claim shared first authorship.

Disclosure
J.Mertens: None. H.T.De winter: None. H.Mazlom: None. F.W.Peiffer: None. E.L.Dirinck: None. N.Bochanen: None. L.Van gaal: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk. C.De block: Advisory Panel; Abbott Diagnostics, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk, Research Support; Indigo Diabetes, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk.